Diabetes implications: The SCALE-Maintenance trial looked at the influence of liraglutide 3.0 mg throughout a 56-week intervention, and as expected, liraglutide users had significantly improved FBG, fasting insulin and HbA1c measurements when compared against placebo participants (Table 1) [51••]. Here, INS is linked to diabetes mellitus.